Baxter, a pharmaceutical company, has notched another mark on its list of corruption scandals. It is now Chile, where the National Economic Prosecutor’s Office (FNE) accuses Mexico’s drugmaker Jaime Alberto Upegui of colluding with another laboratory to jointly award a tender for saline sodium chloride, one of the most commonly used medical supplies in health centers. Both laboratories agreed among themselves to submit proposals to sell above market costs.
This illegal agreement, apparently orchestrated by senior Baxter executives, affected the National Center for Supply of the National Health Services System (Cenabast) and the Concepción Regional Hospital for more than 460 million Chilean pesos (US $700,000 aprox.).
To the list of cases of international corruption of this firm is added a pending judgment in the United States for practices of unfair trade, retaining intravenous solutions to create artificial demand in the market and then increase their prices by up to three hundred percent.
Full Content: Crónica
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Pushes Review of CoStar’s Commercial Real Estate Antitrust Case
Jan 31, 2024 by
CPI
UK’s CMA Investigates Ardonagh’s Atlanta Group and Markerstudy Merger
Jan 31, 2024 by
CPI
Greenberg Traurig Grow Financial Regulatory and Compliance Practice
Jan 31, 2024 by
CPI
Dutch Regulator Fines Uber €10 Million for Privacy Violations
Jan 31, 2024 by
CPI
DOJ Investigates AI Competition, Eyes Microsoft’s OpenAI Deal: Bloomberg
Jan 31, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Rule(s) of Reason
Jan 29, 2024 by
CPI
Evolving the Rule of Reason for Legacy Business Conduct
Jan 29, 2024 by
CPI
The Object Identity
Jan 29, 2024 by
CPI
In Praise of Rules-Based Antitrust
Jan 29, 2024 by
CPI
The Future of State AG Antitrust Enforcement and Federal-State Cooperation
Jan 29, 2024 by
CPI